In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.
J Med Microbiol
; 72(2)2023 Feb.
Article
em En
| MEDLINE
| ID: mdl-36763081
ABSTRACT
Introduction. Piperacillin/tazobactam and carbapenems are important agents for the treatment of serious Gram-negative infections in hospitalized patients. Resistance to both agents is a significant concern in clinical isolates of Enterobacterales and Pseudomonas aeruginosa; new agents with improved activity are needed.Gap Statement. Publication of current, region-specific data describing the in vitro activity of newer agents such as imipenem/relebactam (IMR) against piperacillin/tazobactam-resistant and carbapenem-resistant Enterobacterales and P. aeruginosa are needed to support their clinical use.Aim. To describe the in vitro activity of IMR against non-Morganellaceae Enterobacterales (NME) and P. aeruginosa isolated from bloodstream, intra-abdominal and urinary tract infection samples by hospital laboratories in Western Europe with a focus on the activity of IMR against piperacillin/tazobactam-resistant and meropenem-resistant isolates.Methodology. From 2018 to 2020, 29 hospital laboratories in six countries in Western Europe participated in the SMART global surveillance programme and contributed 9487 NME and 1004 P. aeruginosa isolates. MICs were determined by CLSI broth microdilution testing and interpreted by EUCAST (2021) breakpoints. ß-Lactamase genes were identified in selected isolate subsets (2018-2020) and oprD sequenced in molecularly characterized P. aeruginosa (2020).Results. IMR (99.4â% susceptible), amikacin (98.0â%), meropenem (97.7â%) and imipenem (97.6â%) were the most active agents against NME; 83.1â% of NME were piperacillin/tazobactam-susceptible. Relebactam increased imipenem susceptibility of NME from Italy by 8.3â%, from Portugal by 2.9â%, and from France, Germany, Spain and the UK by <1â%. In total, 96.4â% of piperacillin/tazobactam-resistant (n=1601) and 73.7â% of meropenem-resistant (n=152) NME were IMR-susceptible. Also, 0.4â% of NME were MBL-positive, 0.9â% OXA-48-like-positive (MBL-negative) and 1.5â% KPC-positive (MBL-negative). Amikacin (95.4â% susceptible) and IMR (94.1â%) were the most active agents against P. aeruginosa; 81.7â% of isolates were imipenem-susceptible and 79.6â% were piperacillin/tazobactam-susceptible. Relebactam increased susceptibility to imipenem by 12.5â% overall (range by country, 4.3-17.5â%); and by 30.7â% in piperacillin/tazobactam-resistant and 24.3â% in meropenem-resistant P. aeruginosa. In total, 1.6â% of P. aeruginosa isolates were MBL-positive. Seven of eight molecularly characterized IMR-resistant P. aeruginosa isolates from 2020 were oprD-deficient.Conclusion. IMR may be a potential treatment option for bloodstream, intra-abdominal and urinary tract infections caused by NME and P. aeruginosa in Western Europe, including infections caused by piperacillin/tazobactam-resistant and meropenem-resistant isolates.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por Pseudomonas
/
Infecções Urinárias
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Revista:
J Med Microbiol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos